CagriSema (RUO) — Research-Grade Peptide | COA Verified

Product Specifications

Product Name : CagriSema (Sema / Cagrilintide Blend)
Product Type : Dual-Agonist Peptide Combination
CAS Number : 910463-68-2 (Sema); 1415456-99-3 (Cagrilintide)
Molecular Weight : ~4113.6 g/mol (Sema); ~3974.4 g/mol (Cagrilintide)
Purity : ≥99% (HPLC Verified)
Solubility : Compatible with commonly used laboratory-grade aqueous solvents
Form : Lyophilized Powder
Storage : Store at -20°C, protected from light and moisture

Disclaimer

For Research Use Only (RUO). Not for human use.

Description

Chemical Identity & Characteristics

CagriSema represents a fixed-dose combination (FDC) of two active pharmaceutical ingredients (APIs) targeting distinct receptor systems. The first component, Sema, is characterized as a long-acting Glucagon-Like Peptide-1 (GLP-1) receptor agonist. The second component, Cagrilintide, is identified as a long-acting analogue of amylin and a calcitonin receptor agonist.

In research formulations, these peptides are often co-formulated to investigate the simultaneous activation of the GLP-1 receptors in the pancreas and CNS, alongside amylin receptors (AMY1R/AMY3R) and calcitonin receptors found in the brainstem. The molecular structure involves modifications to the native peptide sequences to enhance stability and prolong the half-life in experimental models.

Molecular comparison of Sema and Cagrilintide

The graphic titled “CagriSema: Molecular Components – Dual Agonist Therapy” presents two molecular diagrams separated by a vertical line. On the left is sema, labeled as a GLP-1 receptor agonist, shown as a detailed chemical structure with colored atoms (e.g., oxygen in red, nitrogen in blue, sulfur in yellow). On the right is cagrilintide, labeled as an amylin receptor agonist, featuring a prominent yellow lipid chain annotated to emphasize “lipid half-life,” indicating the lipid modification used to extend the molecule’s duration of action.

” data-image-caption=”

CagriSema combines sema (GLP-1 receptor agonist) and cagrilintide (lipid-modified amylin receptor agonist) as a dual-agonist therapy.

” data-large-file=”https://profoundaminos.com/wp-content/uploads/2025/05/CagriSema-Molecular-Components-Dual-Agonist-Therapy-1024×768.webp” class=” wp-image-103740″ src=”https://licensebpeptides.com/wp-content/uploads/2026/06/CagriSema-Molecular-Components-Dual-Agonist-Therapy-300×225-1.webp” alt=”CagriSema – Side-by-side chemical structures showing sema (a GLP-1 receptor agonist) and cagrilintide (an amylin receptor agonist) with a highlighted lipid modification indicating extended half-life.” width=”391″ height=”293″ srcset=”https://licensebpeptides.com/wp-content/uploads/2026/06/CagriSema-Molecular-Components-Dual-Agonist-Therapy-300×225-1.webp 300w, https://profoundaminos.com/wp-content/uploads/2025/05/CagriSema-Molecular-Components-Dual-Agonist-Therapy-1024×768.webp 1024w, https://profoundaminos.com/wp-content/uploads/2025/05/CagriSema-Molecular-Components-Dual-Agonist-Therapy-768×576.webp 768w, https://profoundaminos.com/wp-content/uploads/2025/05/CagriSema-Molecular-Components-Dual-Agonist-Therapy-1536×1152.webp 1536w, https://profoundaminos.com/wp-content/uploads/2025/05/CagriSema-Molecular-Components-Dual-Agonist-Therapy.webp 2048w” sizes=”auto, (max-width: 391px) 100vw, 391px”>

showing the lipid modifications that extend stability for research applications.

In research formulations, these peptides are often co-formulated to investigate the simultaneous activation of the GLP-1 receptors in the pancreas and CNS…

Analytical Validation & Certificate of Analysis (COA)

Profound Aminos prioritizes analytical transparency for all research materials. Each batch of CagriSema undergoes rigorous testing to verify identity and purity.

High-Performance Liquid Chromatography (HPLC): Used to assess the purity percentage of the combined peptides and identify potential impurities.

Mass Spectrometry (MS): Utilized to verify the molecular weight and identity of both Sema and Cagrilintide components.

A Certificate of Analysis (COA) is available for every lot, ensuring that researchers receive materials that meet strict specifications for laboratory experimentation. This documentation provides traceability and confirms that the material has been characterized effectively before shipment.

Storage, Stability & Handling (RUO)

This product is supplied as a sterile, lyophilized powder. To maintain stability and integrity :

Storage : Vials should be stored at -20°C in a freezer.
Protection : Keep vials away from direct light and moisture.
Reconstitution : For laboratory preparation and analytical procedures only. Once reconstituted, the solution should be handled according to standard laboratory protocols for peptide stability, typically requiring refrigeration and use within a short timeframe.

This material is hygroscopic and should be allowed to reach room temperature before opening to prevent moisture absorption.

Research Context & Literature Overview

CagriSema has been the subject of extensive investigation in metabolic research, particularly regarding the concept of dual-agonism. Scientific literature describes the combination as targeting non-redundant pathways: the GLP-1 receptor pathway and the amylin/calcitonin receptor pathway.

Published studies report the following mechanistic observations :

In Vitro Analysis : Cellular studies indicate that the combination of GLP-1 and amylin signaling cascades may generate additive cAMP responses in pancreatic beta cells.

Preclinical Models : In rodent studies, the co-administration of these peptides has been observed to modulate receptor signaling pathways distinct from single-agent administration.

Pathway Synergies : Research suggests that while Sema targets hypothalamic areas, Cagrilintide engages receptors in the brainstem (Area Postrema and Nucleus of the Solitary Tract), creating a dual-action receptor engagement profile in animal models.

Metabolic Signaling : Preclinical data indicate that the amylin component acts via distinct receptor pathways utilized in metabolic research models.

Cited Research & Clinical Literature

The following high-impact peer-reviewed journals have published data regarding the characterization of the CagriSema combination. These citations are provided for educational and research contexts only.

New England Journal of Medicine (2025) :

Study: “Cagrilintide–Sema in adults with overweight or obesity and type 2 diabetes.”
Summary: This pivotal Phase 3 research (REDEFINE 1 & 2) documented the characterization of the compound in relevant study cohorts.

Nature Communications :

Context: Published findings discussing the synergistic activation of complementary metabolic pathways and the potential for dual-agonist effects in preclinical models.

The Lancet (Historical Context) :

Context: Earlier foundational studies (Phase 2) established the pharmacological characteristics of the cagrilintide and sema co-administration.

Why Researchers Source from Profound Aminos

Profound Aminos supplies peptides with an emphasis on analytical transparency, lot-level documentation, and strict RUO compliance to support reproducible research.

Traceability : We provide verified data for every batch, ensuring you know exactly what is in your reagent.

Documentation : Clear, accessible COAs support your laboratory’s quality control requirements.

Compliance : We adhere to a strict Research Use Only mandate, ensuring our catalog is accessible to qualified researchers for legitimate scientific inquiry.

Integrity : Our peptides are handled and stored under optimal conditions to preserve experimental validity.

Scientific Reference Disclaimer

The literature citations and research context provided above are strictly for scientific and educational purposes to describe the peptide’s mechanism of action and history in research. They do not imply efficacy, safety, or therapeutic use. This product is a chemical reagent and has not been approved for any medical application.

Regulatory & Compliance Statement

For Research Use Only (RUO).

This product is intended solely for laboratory research and development. It is not for human or veterinary use. It is not a food, drug, or cosmetic.

No medical, therapeutic, or diagnostic claims are made regarding this product. All handling must be performed by qualified professionals in a laboratory setting.